India Osteoarthritis Therapeutics Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Knee osteoarthritis is rising, thereby forming a bigger market for medication, injectables, and interventions for this condition in India. The prevalence of knee osteoarthritis in elderly Indian population was projected to be 47% in a systematic review and meta-analysis published in 2025, though with high variation in prevalence estimates across different populations. Such high prevalence in older people ensures the need for further therapy of this kind. Meanwhile, the prevalence of osteoarthritis is increasing among young adults, thus ensuring a chance for early intervention in this disease. Such changes are making the demand for osteoarthritis treatments stronger.

Intra-articular treatment is gaining importance within India's knee osteoarthritis management landscape because it allows therapeutic agents to be delivered directly into the affected joint. Hyaluronic acid and platelet-rich plasma (PRP) are receiving continued clinical attention, particularly for patients seeking alternatives to repeated oral medication or surgery. An Indian comparative study published in February 2025 evaluated PRP against hyaluronic acid for knee osteoarthritis, reflecting continued investigation of these approaches within the country's clinical setting. The trend is also supported by the emergence of cell-based intra-articular therapy, creating a broader injectable segment encompassing viscosupplementation, autologous biologics and regenerative products, thereby driving the growth of India osteoarthritis therapeutics market.

The Indian market is now slowly progressing away from symptomatic treatment to regenerative treatment options. While traditional analgesics and anti-inflammatory medicines focus on pain relief and inflammation control, regenerative treatments are focused on affecting the biological process related to joint deterioration. Cipla's launch of Ciplostem in December 2025 is particularly significant because it brought an approved allogeneic mesenchymal stromal cell therapy for Grade II and III knee osteoarthritis into the Indian market. Continued clinical research into cell therapies, cartilage preservation and orthobiologics could encourage pharmaceutical companies and biotechnology developers to invest in treatments that potentially offer longer-lasting benefits than conventional symptom-control medicines.

There are now increasing numbers of ways to alleviate osteoarthritis through non-surgical pain management options that can control the symptoms without the need for surgery, including intra-articular injections, PRP therapy, hyaluronic acid, and various interventional pain management techniques like radiofrequency ablation. The setting up of a state-of-the-art RFA center at AIIMS Gorakhpur in March 2026 shows how such sophisticated non-surgical pain management centers are being established even outside India’s biggest cities. Increasing availability of these interventions can therefore broaden the therapeutic pathway and create additional demand beyond conventional oral analgesics and NSAIDs, thus shaping new trends in the India osteoarthritis therapeutics market.

Osteoarthritis management in India is increasingly moving toward earlier intervention and patient-specific treatment selection, particularly as cases are being recognised among younger adults. A June 2026 report highlighted increasing osteoarthritis among people in their 30s and emphasised personalised treatment approaches, while clinical research continues to investigate factors such as obesity, previous joint injury and individual disease characteristics. This creates opportunities for therapies tailored to disease severity, patient age, joint condition and treatment response. Rather than relying on a uniform progression from analgesics to surgery, providers are increasingly considering combinations of medication, injections, rehabilitation and interventional procedures according to individual patient requirements.